Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 3/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186924 | 1.00 | GLS (0.34) | GLSHTR1DNOS2CCKBRTSHR | |
| SCHEMBL20141133 | 0.82 | ADAMTS5 (0.36) | GLSHTR1D | |
| SCHEMBL20141335 | 0.77 | ADRB1 (0.38) | NOS2 | |
| SCHEMBL25835992 | 0.66 | ALDH1A1 (0.42) | CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL20133756 | 0.65 | GRIN2B (0.43) | CYP2C9CYP2D6GRIN2BCYP2C19 | |
| SCHEMBL22693288 | 0.65 | GRIN2B (0.43) | CYP2C9CYP2D6GRIN2BCYP2C19 | |
| SCHEMBL24251635 | 0.65 | ALDH1A1 (0.59) | CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL25836000 | 0.65 | PPARG (0.43) | TSHRCYP2C9CYP1A2CYP2C19 | |
| SCHEMBL14446963 | 0.64 | ALDH1A1 (0.52) | CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL20323537 | 0.64 | GLA (0.43) | TSHRCYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | GLS 517/4885HTR1D 2782/4885NOS2 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.